Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosnilimab (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms RENOIR

Most Recent Events

03 Mar 2026 According to an AnaptysBio media release, company anticipates providing an update on advancement of the trial, which would be funded by strategic or other outside sources of capital, in Q2 2026.
29 Oct 2025 According to an AnaptysBio media release, Phase 2 top-line data through Week 12 for rosnilimab in ulcerative colitis is anticipated in November/December 2025.
29 Oct 2025 Results presented in an AnaptysBio Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com